| Title |
Missed therapeutic and prevention opportunities in women with BRCA‐mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature
|
|---|---|
| Published in |
CA: A Cancer Journal for Clinicians , September 2017
|
| DOI | 10.3322/caac.21408 |
| Pubmed ID | |
| Authors |
Paul J. Hoskins, Walter H. Gotlieb |
| Abstract |
Answer questions and earn CME/CNE Fifteen percent of women with epithelial ovarian cancer have inherited mutations in the BRCA breast cancer susceptibility genes. Knowledge of her BRCA status has value both for the woman and for her family. A therapeutic benefit exists for the woman with cancer, because a new family of oral drugs, the poly ADP-ribose polymerase (PARP) inhibitors, has recently been approved, and these drugs have the greatest efficacy in women who carry the mutation. For her family, there is the potential to prevent ovarian cancer in those carrying the mutation by using risk-reducing surgery. Such surgery significantly reduces the chance of developing this, for the most part, incurable cancer. Despite these potential benefits, referral rates for genetic counseling and subsequent BRCA testing are low, ranging from 10% to 30%, indicating that these therapeutic and prevention opportunities are being missed. The authors have reviewed the relevant available literature. Topics discussed are BRCA and its relation to ovarian cancer, the rates of referral for genetic counseling/BRCA testing, reasons for these low rates, potential strategies to improve on those rates, lack of effectiveness of current screening strategies, the pros and cons of risk-reducing surgery, other prevention options, and the role and value of PARP inhibitors. CA Cancer J Clin 2017. © 2017 American Cancer Society. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 13 | 42% |
| Mexico | 3 | 10% |
| United Kingdom | 2 | 6% |
| Sweden | 1 | 3% |
| Brazil | 1 | 3% |
| Canada | 1 | 3% |
| Unknown | 10 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 58% |
| Scientists | 5 | 16% |
| Science communicators (journalists, bloggers, editors) | 4 | 13% |
| Practitioners (doctors, other healthcare professionals) | 4 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 105 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 15% |
| Researcher | 10 | 10% |
| Student > Master | 10 | 10% |
| Student > Doctoral Student | 7 | 7% |
| Other | 7 | 7% |
| Other | 24 | 23% |
| Unknown | 31 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 27% |
| Biochemistry, Genetics and Molecular Biology | 12 | 11% |
| Nursing and Health Professions | 6 | 6% |
| Unspecified | 5 | 5% |
| Social Sciences | 4 | 4% |
| Other | 14 | 13% |
| Unknown | 36 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2022.
All research outputs
#1,924,643
of 25,382,440 outputs
Outputs from CA: A Cancer Journal for Clinicians
#310
of 1,031 outputs
Outputs of similar age
#36,547
of 323,159 outputs
Outputs of similar age from CA: A Cancer Journal for Clinicians
#7
of 12 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,031 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 78.9. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.